The research interests of Michael G. Haddock, M.D., involve integrating radiation therapy with systemic therapy in the management of gastrointestinal (GI) and gynecologic (GYN) malignancies, and the use of intraoperative radiation therapy (IORT) in the management of locally advanced GI and GYN malignancies.
- IORT as a radiation dose escalation tool. The Mayo Clinic IORT program is focused on improving local control of cancer growth in selected patients with GI, GYN and genitourinary malignancies, as well as those with soft tissue sarcomas. It is the largest program in North America for nonbreast cancer indications.
- Combined systemic therapy and radiation therapy for GI and GYN malignancies. Dr. Haddock participated in the design and completion of clinical trials through the National Cancer Institute's cooperative group mechanism to evaluate the use of systemic agents as radiosensitizers.
Significance to patient care
Patients with locally advanced primary or recurrent malignancies have a high rate of local recurrence after surgery and standard radiation therapy. Local recurrence, especially in the pelvis, is associated with significant morbidity. Radiation dose escalation with IORT has resulted in significantly improved local control, especially in patients who have previously been irradiated.
- Principal investigator, Intraoperative Radiation Therapy Database, 2001-present
- Investigator for numerous cooperative group clinical trials, Radiation Therapy Oncology Group (RTOG), American College of Radiology, 1994-present
- Vice chair, Gastrointestinal Committee, North Central Cancer Treatment Group, 2009-2011
- Vice chair of the gastrointestinal and sarcoma committee, American College of Surgeons Oncology Group, 2004-2011